Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic natural killer cells + cetuximab
- Development stage
- Unknown
- Lead developer
- CHU de Besançon
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraarterial, Intravenous
01
Overview
This investigational cell-based immunotherapy is a combination treatment developed by the Centre Hospitalier Universitaire de Besançon for the treatment of EGFR-positive metastatic gastrointestinal cancers with liver involvement. The regimen consists of allogeneic (donor-derived) haploidentical natural killer (NK) cells administered via hepatic intraarterial infusion, combined with the anti-EGFR monoclonal antibody cetuximab. The therapeutic strategy relies on the synergistic effect of direct NK cell-mediated cytotoxicity and cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC). To support the persistence and activity of the infused NK cells, the protocol includes a lymphodepleting conditioning regimen of cyclophosphamide and fludarabine, followed by the administration of high-dose interleukin-2 (IL-2).
- Other names
- haploidentical natural killer cellsNK cell immunotherapyallogenic immunotherapy based on Natural Killer cells adoptive transfer
02
Targets
EGFR (Epidermal growth factor receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on allogeneic natural killer cells + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic natural killer cells + cetuximab.